Financial Performance - Johnson & Johnson's adjusted earnings per share of $2.80 beat expectations of $2.76 [1] - Johnson & Johnson's revenue reached $23.99 billion, surpassing the consensus of $23.8 billion [1][2] - The company is raising its full-year sales outlook, projecting $93.7 billion in revenue for 2025, exceeding the street's expectation of $93.4 billion [1][2] - Johnson & Johnson reaffirms its full-year guidance for adjusted earnings per share, estimating $10.80 to $10.90, aligning with the street's expectation of $10.86 [2] Business Strategy - Johnson & Johnson plans to separate its orthopedics business into a standalone entity named Dew Cthus [3] - The separation of the orthopedics business is expected to be completed within the next 18 to 24 months [3] - The orthopedics business accounts for approximately 9% to 10% of Johnson & Johnson's overall sales, amounting to around $9.2 billion [3] Market Reaction - Johnson & Johnson's shares are up by about 125% [4]

强生发布财报，第三季度销售额239.9亿美元，预计财年销售额为935亿美元至939亿美元。强生美股盘 前一度涨2.4%。 （文章来源：第一财经） ...

| | | 03 | | | --- | --- | --- | --- | | ($ in Millions, except EPS) | 2025 | 2024 | % Change | | Reported Sales | $23,993 | $22,471 | 6.8% | | Net Earnings | $5,152 | $2,694 | 91.2% | | EPS (diluted) | $2.12 | $111 | 91.0% | | | | Q3 | | | Non-GAAP* ($ in Millions, except EPS) | 2025 | 2024 | % Change | | Operational Sales1 | | | 5.4% | | Adjusted Operational Sales10 | | | 4.4% | | Adjusted Net Earnings14 | $6,801 | $5,876 | 15.7% | | Adjusted EPS (diluted)1/0 | $2.80 | $2.42 | 15.7% | | Free Cash Flow 6.7 ...

格隆汇10月14日｜强生(JNJ.US)预计财年销售额为935亿至939亿美元，此前预期为932亿至936亿美元。 ...

Core Insights - Johnson & Johnson raised its full-year sales outlook due to gains in both its prescription-drug and medical-device businesses in the latest quarter [1] Company Performance - The company reported an increase in sales across its prescription-drug segment, contributing positively to the overall financial outlook [1] - Gains in the medical-device business also played a significant role in enhancing the company's sales projections for the year [1]

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Q4 dividend. ...

强生10月14日发布第三季度业绩显示，销售额239.9亿美元，同比增长6.8%；调整后每股收益2.80美 元，上年同期2.42美元。强生预计全年销售额935亿美元至939亿美元，此前预计932亿美元至936亿美 元，仍然预测调整后每股收益10.80美元至10.90美元。 来源：智通财经 ...

Johnson & Johnson says it plans to separate its slower-growing orthopedics business from the rest of the company within 18 to 24 months https://t.co/jwAdzHkoWU ...

Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20... ...

Core Insights - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,672 million in Q3 2025, with USD 2,088 million from the U.S. and USD 1,584 million from the rest of the world [1][5] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform cancer treatment by 2030 [2] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3]